Who are Surufatinib plus Toripalimab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anlotinib hydrochloride capsules, Penpulimab injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/surufatinib-plus-toripalimab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Surufatinib plus Toripalimab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surufatinib plus Toripalimab (Surufatinib plus Toripalimab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor + PD-1 inhibitor combination. Area: Oncology.

phase 3 Tyrosine kinase inhibitor + PD-1 inhibitor combination FGFR, VEGFR, RET (surufatinib); PD-1 (toripalimab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Surufatinib plus Toripalimab (Surufatinib plus Toripalimab) — Hutchison Medipharma Limited. Surufatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET) to block tumor angiogenesis and growth, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Surufatinib plus Toripalimab TARGET	Surufatinib plus Toripalimab	Hutchison Medipharma Limited	phase 3	Tyrosine kinase inhibitor + PD-1 inhibitor combination	FGFR, VEGFR, RET (surufatinib); PD-1 (toripalimab)
Anlotinib hydrochloride capsules, Penpulimab injection	Anlotinib hydrochloride capsules, Penpulimab injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Multi-target tyrosine kinase inhibitor + PD-1 inhibitor combination	VEGFR, FGFR, RET, KIT (anlotinib); PD-1 (penpulimab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor + PD-1 inhibitor combination class)

Hutchison Medipharma Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Surufatinib plus Toripalimab — Competitive Intelligence Brief. https://druglandscape.com/ci/surufatinib-plus-toripalimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab